ALLR Allarity Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1860657 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-2.7%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-3,938.3%
Net margin-4,493.7%
FCF margin-3,785.4%
EBITDA margin—
Returns
ROE-322.7%
ROA-65.5%
ROIC (approx.)—
Asset turnover0.01x
Leverage & solvency
Liabilities / assets108.3%
Debt / equity—
Current ratio0.91x
Interest coverage-6.83x
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-10.6%
Payout ratio—
Capex / revenue20.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $320,000 | $0 |
| R&D expense | $6.60M | $6.10M |
| SG&A expense | $6.32M | $11.44M |
| Operating income | -$12.61M | -$27.24M |
| Interest expense | $185,000 | $653,000 |
| Pretax income | -$11.23M | -$24.90M |
| Income tax | $0 | -$381,000 |
| Net income | -$11.23M | -$24.52M |
| EBITDA | — | -$27.23M |
| EPS (basic) | -0.78 | -15.65 |
| EPS (diluted) | — | — |
| Balance sheet | ||
| Cash & equivalents | $14.69M | $19.53M |
| Current assets | $17.93M | $22.34M |
| PP&E, net | $330,000 | $309,000 |
| Intangibles | — | $0 |
| Total assets | $18.26M | $22.65M |
| Current liabilities | $8.43M | $10.84M |
| Short-term debt | $0 | — |
| Total liabilities | $8.43M | $10.84M |
| Shareholders' equity | $9.83M | $11.81M |
| Shares outstanding | 16.08M | 7.30M |
| Cash flow statement | ||
| Operating cash flow | -$14.82M | -$17.35M |
| Capital expenditure | $8,000 | $298,000 |
| Free cash flow | -$14.83M | -$17.65M |
| Investing cash flow | -$8,000 | -$298,000 |
| Financing cash flow | $10.65M | $36.79M |
| Depreciation & amortization | — | $9,000 |
| Stock-based compensation | $482,000 | $71,000 |
| Share buybacks | $3.19M | $0 |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.